A promising new antibiotic, sorfequiline, could transform global tuberculosis treatment by curing patients faster and reducing reliance on lengthy drug regimens, according to trial results presented at the Union Conference on Lung Health. In a study involving 309 patients across five countries, the drug showed stronger antibacterial action than current therapies while maintaining similar safety levels. Researchers say sorfequiline could become a universal regimen, allowing doctors to begin treatment immediately without waiting for diagnostic classifications—a major advantage in regions with slow testing. This simpler, shorter approach could boost cure rates and help health systems manage the disease more efficiently. A larger, phase-3 clinical trial is planned for 2026, marking a hopeful new chapter in the effort to end tuberculosis.
The Guardian
